2006 in London

2006 fatal poisoning of a former FSB and KGB officer

2006 edition of the BAFTAs

Theralizumab (also known as TGN1412, CD28-SuperMAB, and TAB08) is an immunomodulatory drug developed by immunologist of the University of Würzburg. It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by Parexel in London in March 2006. The developing company, TeGenero Immuno Therapeutics (), a spin-off of the University of Würzburg around immunologist Thomas Hünig, co-founder and chief scientific officer (CSO) Thomas Hanke and chief executive officer (CEO) Benedikte Hatz went bankrupt later that year. The c

Congolese student

2006 edition of annual pop music awards ceremony

former London Underground station

2006 British film awards ceremony

9th British Independent Film Awards